2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis | Arthritis and Rheumatology | 2016 | 1.3K |
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 | Lancet, The | 2016 | 791 |
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis | Arthritis Care and Research | 2016 | 717 |
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs | Journal of Pharmaceutical Sciences | 2016 | 416 |
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial | Journal of Hepatology | 2016 | 407 |
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation | European Heart Journal | 2016 | 319 |
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study | Journal of Hepatology | 2016 | 189 |
Ethylene vinyl acetate (EVA) as a new drug carrier for 3D printed medical drug delivery devices | European Journal of Pharmaceutical Sciences | 2016 | 173 |
A comprehensive insight on ocular pharmacokinetics | Drug Delivery and Translational Research | 2016 | 167 |
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF | European Heart Journal | 2016 | 167 |
Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing | ALTEX: Alternatives To Animal Experimentation | 2016 | 161 |
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults | JAMA Neurology | 2016 | 157 |
Three-Dimensional Printed PCL-Based Implantable Prototypes of Medical Devices for Controlled Drug Delivery | Journal of Pharmaceutical Sciences | 2016 | 147 |
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas | Annals of Oncology | 2016 | 140 |
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use | Blood | 2016 | 122 |
Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides | Proceedings of the National Academy of Sciences of the United States of America | 2016 | 112 |
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876 | ChemMedChem | 2016 | 108 |
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation | Circulation | 2016 | 102 |
Structural analysis of human KDM5B guides histone demethylase inhibitor development | Nature Chemical Biology | 2016 | 102 |
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial | Lancet Respiratory Medicine,the | 2016 | 98 |
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF | Journal of the American Heart Association | 2016 | 94 |
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF | Circulation | 2016 | 93 |
Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry | International Journal of Stroke | 2016 | 86 |
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis | Arthritis and Rheumatology | 2016 | 69 |
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial | Lancet Respiratory Medicine,the | 2016 | 69 |